Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies |
| |
| Institution: | 1. Celdara Medical LLC, Lebanon, NH, 16 Cavendish Ct Suite 240, Lebanon, NH 03766, USA;2. Center for Synthetic Immunity and Department of Microbiology & Immunology, Geisel School of Medicine at Dartmouth, One Medical Center Dr., Lebanon, NH 03765, USA;1. Pediatric Oncology Branch, Bethesda, MD, USA;2. Experimental Transplantation and Immunology Branch, Bethesda, MD, USA;3. Laboratory of Pathology, Bethesda, MD, USA;4. Surgery Branch, Bethesda, MD, USA;5. Biostatistics and Data Management Section, Office of the Clinical Director, National Cancer Institute, Bethesda, MD, USA;6. Cell Processing Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA;7. National Institutes of Health Medical Student Training Program, The University of Nevada School of Medicine, Reno, NV, USA;8. Children''s Center for Cancer and Blood Diseases, Division of Hematology, Oncology and Blood and Marrow Transplantation, Children''s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA;1. Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA;2. Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, CA 90095, USA;3. Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, CA 90095, USA;1. State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China;2. Life Science and Clinical Research Center, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi Province, China;3. Department of Neurosurgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China;4. Department of Otolaryngology, Head and Neck Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan Province, China;1. Department of Hematology and Medical Oncology, University Hospital Wuerzburg, Versbacherstrasse 5, 97078 Wuerzburg, Germany;2. Myeloma Service, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY 10065, New York, USA;1. Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA, USA;2. Harvard Medical School, Boston, MA, USA |
| |
| Abstract: | Chimeric antigen receptors (CAR)-T cell therapy has recently made promising advances towards treatment of B-cell malignancies. This approach makes use of an antibody-derived single chain variable fragment (scFv)-based CAR to target the CD19 antigen. Currently scFvs are the most common strategy for creation of CARs, but tumor cells can also be targeted using non-antibody based approaches with designs focused on the interaction between natural receptors and their ligands. This emerging strategy has been used in unique ways to target multiple tumor types, including solid and haematological malignancies. In this review, we will highlight the performance of receptor-ligand combinations as designs for CARs to treat cancer, with a particular focus on haematologic malignancies. |
| |
| Keywords: | NKG2D Cytokines Cell therapy Immunotherapy T cell |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
